Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-INCLINE: REGN7508 and REGN9933 for Stroke Prevention in Atrial Fibrillation
NCT07430956Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of REGN7508, amrecibart in Atrial fibrillation (AFib), sponsored by Regeneron Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
REGN7508amrecibart
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07430956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07430956.